Revolution Medicines, Inc. ((RVMD)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing ...
Results from the trial's first year were reported at the 2024 ACR meeting, and they persuaded the FDA to approve the drug for ...
The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for ...
Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...
1 Graduate School, Heilongjiang University of Chinese Medicine, Harbin, China 2 First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China Rheumatoid Arthritis (RA) is a ...
Patients with rheumatoid arthritis (RA) tolerated a novel Janus kinase/Roh-associated protein kinase (JAK-ROCK) inhibitor without typical side effects. Phase 2 clinical trial at nine hospitals and ...
Now, the work presented at the 2025 annual EULAR congress in Barcelona adds two important pieces to the puzzle. First, a large-scale real-world study reporting no significantly higher risk of cancer ...
Please provide your email address to receive an email when new articles are posted on . JAK inhibitors were not linked to increased cardiovascular complications vs. TNF inhibitors or other DMARDs in ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. In The Lancet Rheumatology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback